Eli Lilly Sues Wellness Groups Over Knockoff Weight Loss Drugs

Eli Lilly & Co. sued online vendors and medical spas for selling products containing tirzepatide, the primary ingredient in its blockbuster GLP-1 weight-loss drugs Mounjaro and Zepbound, without federal approval.

The pharmaceutical giant on Monday sued Pivotal Peptides LLC, Mangoceuticals Inc., and Genesis Lifestyle Medicine of Nevada LLC. The complaints were filed respectively in the US District Courts for the Districts of the Western District of Washington, Northern District of Texas, and Southern District of Indiana.

In its filings, Lilly said Pivotal Peptide’s “litany of false and misleading statements undermines and cheapens the unique trust consumers place in Lilly and ...